But according to the report, there is a large amount of variability in drug and dose schedule, and adverse event reporting in cancer in publications.[4] Based on pooled data from pivotal trials as reported by the European Medicines Agency, the present paper reviews incidences and kinetics of onset and resolution of immune-mediated “adverse events of specific interest” (AEOSI) of both approved PD-1 inhibitors nivolumab and pembrolizumab. This evidence concerns the gene PDCD1 and cancer.